Get the Stockscreener App
4.47
1.11%
-0.05
After Hours:
4.49
0.02
+0.45%
Lipocine Inc Stock (LPCN) Latest News
Postpartum Depression Market Expected to rise, 2034 | Pfizer, Sage Therapeutics, Lipocine Inc, Eli Lilly and Company, GSK, Canopie, Talkspace, expected to drive market - Barchart
Lipocine (NASDAQ:LPCN) Now Covered by Analysts at StockNews.com - Defense World
Lipocine Updates Corporate Presentation, Files 8-K with SEC - Defense World
StockNews.com Initiates Coverage on Lipocine (NASDAQ:LPCN) - Defense World
(LPCN) On The My Stocks Page - Stock Traders Daily
StockNews.com Begins Coverage on Lipocine (NASDAQ:LPCN) - Defense World
Light Vision 2024 Shenzhen International Optics Fair - GlobeNewswire Inc.
FDA Grants Fast Track Designation to Lipocine (NASDAQ:LPCN) for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis - Defense World
Lipocine Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits - Quantisnow
FDA fast tracks Lipocine's sarcopenia treatment - Investing.com
FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis - PR Newswire
FDA Grants Fast Track Designation to LPCN 1148 as Treatment for Sarcopenia - Contract Pharma
Lipocine (NASDAQ:LPCN) Now Covered by StockNews.com - Defense World
Lipocine to Present at H.C. Wainwright 8th Annual MASH Investor Conference - The Eastern Progress Online
Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session - The Eastern Progress Online
Where are the Opportunities in (LPCN) - Stock Traders Daily
Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024 - The Eastern Progress Online
Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference - The Eastern Progress Online
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024 - GuruFocus.com
Lipocine Announces Supply and Distribution Agreement with Pharma - GuruFocus.com
Lipocine (NASDAQ:LPCN) Announces Financial Results for the Quarter Ended September 30, 2024 - Defense World
When the Price of (LPCN) Talks, People Listen - Stock Traders Daily
Lipocine: Q3 Earnings Snapshot - CT Insider
Lipocine Inc. (LPCN) Quarterly 10-Q Report - Quartz
Lipocine Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Lipocine (NASDAQ:LPCN) Presents Positive Data on LPCN 2401 at Obesity Society Conference - Defense World
Lipocine inks deal to bring TLANDO to South Korea - Investing.com
Lipocine Partners With SPC Korea For TLANDO In South Korea - Contract Pharma
Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South Korea - Morningstar
Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study i - GuruFocus.com
Trading (LPCN) With Integrated Risk Controls - Stock Traders Daily
Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1 - GuruFocus.com
Lipocine Announces Completion of Dosing in Pivotal Study of Post - GuruFocus.com
(LPCN) Trading Signals - Stock Traders Daily
Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Bod - GuruFocus.com
Lipocine reports promising oral brexanolone study results By Investing.com - Investing.com Australia
Lipocine reports promising oral brexanolone study results - Investing.com India
Lipocine Enters Exclusive Supply And Distribution Agreement With Pharmalink - Contract Pharma
Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results - PR Newswire
Lipocine signs supply and distribution agreement with Pharmalink for Tlando - Yahoo Finance
Lipocine partners with Pharmalink for GCC distribution of TLANDO - Investing.com
Lipocine partners with Pharmalink for GCC distribution of TLANDO By Investing.com - Investing.com Nigeria
Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Countries - PR Newswire
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):